Health Meaning

A Christian group has filed a lawsuit against the National Institutes of Health, alleging that the policy on stem cell administration Obama violates federal law, reports the online journal Kansas Liberty.com .

The complaint was filed with the Federal District Court in Washington, DC, by James L. Sherley, a researcher of adult stem cells in biomedical research institute Boston and Theresa Deisher, R & D Director AVM Biotechnology in Seattle, Washington. It is supported by, among others, Nightlight Christian Adoptions, a group that promotes the adoption of embryos left-over from fertility clinics. Sherley, he can remember, is the former Massachusetts Institute of Technology professor who made a hunger strike in 07 to protest against a lack of diversity of faculty after he refused tenure.

The complainants argue that the federal policy that allows the use of human embryonic stem cells, but not their derivation by scientists funded by the federal, violates the Dickey-Wicker amendment, a provision of the law on the NIH appropriations which prohibits federal beneficiaries to research on human embryos. Federal guidelines "allow public funding for research and that depends, in fact, requires the destruction of living human embryos," the group of reasons.

Tony Mazzaschi of the Association of American Medical Colleges in Washington, said the suit was not "a chance in hell" of success. A similar suit was filed last March in the Maryland District Court US per Night and others.

In an effort to allay growing concerns about the swine flu pandemic, the US Department of Health and Human Services (HHS) released all the stops today spread the news that one dose of a vaccine against the new H1N1 virus is likely to protect adults.

As HHS Secretary Kathleen Sebelius said during a press conference this afternoon, the preliminary results of clinical studies that one dose triggers a strong antibody response in adults "is critical of important news. " Flanked by senior officials of the National Institutes of Health, the Centers for Disease Control and Prevention and the Food and Drug Administration, Sebelius noted that if two doses were needed, as some had predicted, it would take more time to vaccinate the population and require more products. But she also pointed out that the data still exist on how the vaccine works in children and pregnant women, two groups that are at high risk of developing serious illness from the virus. And the time of arrival of the vaccine remains a major concern, she said.

Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases of the NIH, the first data set of adult trials sponsored by the institute. Among people aged 18 to 64 years who received one of two different H1N1 pandemic vaccines, 80% to 96% developed "robust immune response" 8 to 10 days after a single dose of 15 micrograms. Persons 65 and over do not respond as well, with only 56% to 60% to levels similar antibody. the new data grid with data reported yesterday the new England Journal of Medicine tests conducted outside the United States.

the unusual high-level press conference to discuss the preliminary results of clinical studies reflects the high level of anxiety in the country about the pandemic. the new information, Sebelius said, "shortens the window of worry and more people can be protected much earlier." It also means that the limited supply of vaccine, which will not start arriving States STATES until mid-October, can be made available to other people in other countries more quickly.

Yet many experts say it appears that the pandemic could peak in the US in mid-October, before the arrival of the vaccine. "The models are based on assumptions," said Fauci. "While it might be peaks before people get vaccinated, but there are other ways to reduce the spread." Anne Schuchat, head of the CDC's National Center for Immunization and Disease respiratory, stressed that the virus appears in different communities at different times. "We believe that many opportunities for prevention will be possible with the vaccine, especially now that we have this great news that the protection might be possible in adults after this first dose, "said Schuchat.

You should not stay up all night worrying, but a new study has found a link between lack of sleep and a biomolecule thought to be important in the development of the disease Alzheimer.

in humans and mice, the levels of a peptide called amyloid-β place during working hours and declining waking during sleep, the researchers found. They also report that the sleep-deprived mice are more likely to develop amyloid-β deposits, called plaques, like those found in the brains of Alzheimer's patients. Although far from proven, the finding suggests that sleep disturbances may be a risk factor for Alzheimer's disease. On a brighter note, he also alluded to new treatment avenues.

Numerous evidence suggests that naturally occurring amyloid-β in the brain built over many years in people who develop Alzheimer's disease, beginning long before people show signs of loss memory. But very little is known about the factors that may influence peptide levels in the brain, says David Holtzman, a neurologist at Washington University in St. Louis, Missouri.

To study, Holtzman and colleagues conducted a series of experiments with mice in which a small tube is inserted into the brain to take samples of the fluid flowing through the space between the cells. Sampling of the hippocampus, a crucial memory region which is one of the first to be ravaged by Alzheimer's disease, the researchers found that levels of amyloid-β peaked when the animals were awake and fell during sleep. They found a similar pattern in 10 healthy people who agreed to lumbar punctures to allow researchers to sample their cerebrospinal fluid.

The researchers also probed the effects of chronic sleep deprivation in mice that are genetically prone to developing amyloid plaques. To keep awake mice, the researchers placed each on a small platform surrounded by water, which gave them no room to lie down and doze. Mice that stayed awake for 20 hours a day for 3 weeks developed more amyloid plaques than their well-rested peers, the researchers found. Moreover, a drug that blocks orexin receptors, a hormone that promotes wakefulness, reduced plaque formation in the same strain of mice, reports online today in team Science .

The results suggest that people who are chronically sleep deprived may have higher levels of amyloid-β that make them more susceptible to Alzheimer's disease, Holtzman said. He said the team spoke with researchers who do clinical studies of sleep about combing their databases for any signs that people with sleep disorders history are more prone to Alzheimer's disease. "No one has ever studied it," he said. The team will also investigate the use of drugs that interfere with orexin to thwart Alzheimer's disease.

"I find it really cool that sleep is a modulator of the amyloid-β production, "says Sam Sisodia, molecular neurobiologist at the University of Chicago in Illinois. This represents further evidence that amyloid ß rises and falls with levels of synaptic activity, Sisodia said. But the cutting-edge treatments for Alzheimer's disease are far away, he says. "There is another vision, another glimmer of hope."

A striking case in Japan confirmed that pregnant women with cancer can transmit the disease to their fetuses. These transmissions normally blocked by the placenta are rare, so the work will not likely change how doctors screen or care for pregnant women. But scientists say the case could help illuminate how cancer foils the body's immune system.

In early 07, a 28-year-old Japanese woman gave birth to a daughter. Thirty-six days later, the mother was hospitalized with vaginal bleeding, which became uncontrollable. Doctors diagnosed leukemia, and she died soon. The baby developed normally until age 11 months, when a huge tumor appeared in her cheek. A biopsy determined the cancer has not been sarcoma - a cancer of some connective tissues -. But leukemic tumor somehow trapped in the cheek of the child

The doctors alerted cell biologist Mel Greaves of the Institute of Cancer Research in Sutton Surrey, UK, who studies transmissible cancers. Scientists had suspected the mother-fetus cancer in other cases with circumstantial evidence (especially leukemia and melanoma, which both metastasize easily). But nobody had done genetic tests to prove that the cancer had grown from a single source and was not just an unfortunate coincidence.

In their investigation, Greaves and his colleagues discovered incipient cancer cells in routine blood samples taken from the child at birth, which strongly suggests that transmission happened in utero. They also examined a unique DNA sequence in each case of leukemia, BCR-ABL1 sequence. It was identical to the mother and daughter. Finally, the tests showed the cancer cells of children were almost all maternal cells without genetic material from the father. This indicated that the route of transmission is from mother to fetus, and not the reverse. The team has its evidence in a paper published online October 12 in the Proceedings of the National Academy of Sciences .

Greaves and his colleagues also determined how cancer survived inside the fetus, whose immune system would destroy the cells of the mother. They found that the cancer cells are absent a large area from a section of the sixth human chromosome known under the name 6p, which produces surface markers of immune cells which bind to the. In short, Greaves said, "Cancer has succeeded because it was immunologically invisible."

Knowing the molecular details of how evaded detection cells enable scientists to probe how other cancers slide by our immune system, said Howard Weinstein, a pediatric cancer specialist at Massachusetts General Hospital in Boston.

Despite the findings, mothers should not panic, says Greaves. with only a few dozen cases of transmission of cancer mother-fetus reported since the first in 1866, the risk for pregnant women is minimal, he said, and the transfer of advanced cancer in infants are not necessarily fatal. - the Japanese girl was successfully treated and is still alive. But Greaves said his team's work challenges the assumption that the placenta is a fully effective barrier between mothers and fetuses. "I'm more inclined to think that perhaps the cells obtained by modest numbers all the time," he said. "You can learn a lot of very strange case in medicine."

Pandemic make strange bedfellows in this case, advocates of public health and the falcons defense.

Commission on the Prevention of WMD and terrorism posted a video that asks why the United States is still based on a centuries-old technology based on eggs makes its vaccine against influenza. "Do was it would be nice if the H1N1 vaccine had been available for our children to school before the school year began?" Asks former Governor and Senator Bob Graham (D-FL) and former Senator Jim Talent (R-MO).

politics, president and vice president retired from the board, take us back to the year each man graduated from high school to remind us that technology egg-based vaccines is as much a relic as telephone line, disco dancing and the AMC Gremlin. the video does not specify that attempts to move the last eggs are underway in the United States, although it is explained on the website of the commission. But the video, it is clear that when it comes to vaccines against influenza, we live in the technological stone age.

Here is an overview of some of the stories that we followed on science political blog of science Insider:

a petition presented earlier this year at the direction of the American Physical society Council to change the official statement of the company in 07 to climate change fell in (carbon neutral) flames. The 07 statement warned that "if no mitigation measures are taken, significant disruptions in the physical and ecological systems of the Earth, social systems, security and human health are likely to occur."

Leading African science academies say in a report published yesterday in Ghana that the intensification of affordable medical interventions such as vaccination of 20% could save the lives of about 770,000 children and young mothers each year in nine countries in sub-Saharan Africa.

in the new film men who Stare at goats , George Clooney plays a former member of a secret sect of the soldiers trained by the . US military to deploy a weapon against the enemy crowd paranormal fatal their talents are meant the ability to kill a goat by psychokinesis - watching the beast they can make his heart stop with thought alone. The film takes some liberties in the name of comedy, but the program it is based on is real.

Scientists and policy experts will gather in March next year to hash rules for conducting field experiments on the controversial subject of geoengineering . Styled after the Asilomar conference 1975 mark on recombinant DNA, the conference has attracted top scientists to support climate and environmental groups. But he is also facing questions and criticism about its opening and the origins of some of the organizers.

Senator Tom Coburn (R-OK) finally got his call vote to strip long-awaited political science studies of the 2010 budget of National Science Foundation (NSF). And while his amendment was soundly defeated, 36 to 62, it was not strictly a party-line vote. Five moderate Democrats - Senators Max Baucus of Montana, Evan Bayh of Indiana, Claire McCaskill of Missouri, Ben Nelson of Nebraska, and Jim Webb of Virginia - apparently agree with the argument that Coburn NSF, with a budget of $ 6.9 billion is "wasting" federal funds by spending $ 9 million per year to support research in the field.

National Institutes of Health is again taken to task for doing too little to manage potential conflicts of researchers interest, such as consulting for drug companies. This time federal investigators say NIH should strengthen the rules that now provide the ability to NIH funding too much latitude in what they have to report.

The criticism comes from the Department of Health and Human Services (HHS) Inspector General (IG), which in 08 revealed that the NIH did not pay enough attention to how institutions manage its donees conflicts of interest. In a follow-up report dated 18 November, the IG has reviewed the information donees 41 institutions submitted to the NIH in 06, and the documents retained by institutions such as disclosure forms. The most common conflict, he found was equity-owned 111 165 researchers had equity such as shares of a company, and six had equity of a value of over $ 100,000.

Seven members of the faculty received more than $ 50,000 in royalties or compensation. In most cases, the institutions "manage" these conflicts by requiring researchers describe in talks and papers, not get rid of them, the IG found.

The report found "vulnerabilities" in how universities monitor conflicts. For example, 0% of the 41 institutions allow researchers themselves to decide whether their financial interests are related to their research, and about half did not ask for specific amounts. Nor did they check to verify that researchers report honestly.

"There is a need for more transparency about and monitoring of grantees institutions," the report concludes. The report repeats previous advice that NIH make the institutions relate details on how they are managing conflict. It also lists several steps NIH should require institutions such as asking faculty members to report all possible conflicts, not just those they think are relevant, and the collection of specific dollar amounts.

Others have also called on the institutions to gather more information on the conflict, including an Institute of Medicine committee earlier this year. And many of the recommendations of IG HHS appear in a notice published in July on possible modifications regulatory conflicts of interest of public health services. NIH plans to publish proposed regulations in the coming weeks.

biomedical research leaders often complain that the research funding system on specific projects US stifles risk taking and creativity. A better model, they say, would be to give the long-term price researchers unconditionally. Now some MIT economists say they have thoroughly tested this idea for the first time and found that scientists with public funding are indeed more productive and creative.

There are two basic biomedical science funding models in the United States. The National Institutes of Health provides the bulk of its grant money as a 3 or 4-year grants, called R01, for research projects on specific topics with detailed objectives. Then there is the Howard Hughes Medical Institute, the nonprofit giant that supports more than 300 researchers across the country for 5 years or more depending on their qualifications, not personal what they study. "People, not projects" is the mantra of HHMI, and proponents say it supports the most creative science.

But so far there has been no "serious efforts "to test this idea, says MIT economist Pierre Azoulay So he and two colleagues compared the careers of two groups. seventy-three were HHMI investigators who were appointed in the early 190s, and about 400 were scientists of the same age who have received prestigious "early career" from sources such as the Pew Charitable trusts and the Packard Foundation. (About 70% of HHMI investigators started with one of these awards, said Azoulay.) they also compared a group of scientists who received a long term, prestigious, specific to the NIH project, called a MERIT award.

the HHMI investigators clearly won, producing twice as many documents the top 5% of citations as the first career winners, for example, the team concludes AZOULAY in a working paper. They were closer to the MERIT beneficiaries in production, but 50% more written documents in the top 1% by citation. HHMI group were also more likely to change the keywords in their resumes over time, suggesting that they were moving in new directions, creative.

makes sense, but the study to fully control that the HHMI scientists might be more gifted to begin with? "We can not. We are very open about it," said Azoulay. To really know if the type of funding makes a difference, you must assign randomly equally qualified researchers to either get an HHMI-type or R01 funding, who admits he is unlikely to occur.

he adds that the study is not intended as an "exercise NIH-bashing." While the NIH has some new types of awards following HHMI model, such as the price of Pioneer, he does not think the agency should R01 gap altogether, said Azoulay. Science requires a mixture of work "incremental" and "breakthrough", especially to translate the results, he said. And the document concludes:

Only scientists showing outstanding qualities are eligible HHMI appointments and our results may not generalize to the overall population of eligible scientists to a subsidy, which include individuals gifted and those with more modest talent. In addition, HHMI provides a detailed evaluation and feedback to investigators. The richness of this feedback resource intensive, especially the time of elite scientists who serve on review panels, and its quality may deteriorate if the program was expanded drastically.

But Azoulay think NIH is making a mistake now: he is not collecting data, be aware if scientists funded by the new models are more productive effect. "We can never learn how effective it was," he said.

Chalk another win patent to the University of Wisconsin, Madison. Its powerful IP-complement the Wisconsin Alumni Research Foundation (WARF) -appears have knocked a biotechnology partner, Xenon Pharmaceuticals Inc., Burnaby, Canada, said he tried to exploit a discovery laboratories Biochem Wisconsin without paying the university some disputed charges.

researchers from Wisconsin and Xenon worked 9 years ago to study the enzyme stearoyl-CoA desaturase (SCD), the anti-cholesterol they both patented properties. Xenon helped fund this research. But a federal appeals court ruled yesterday that Xenon evil tried to cut his own license agreement with Novartis, excluding WARF, create drugs based SCD. The Seventh Circuit Court of Appeals backed a lower court that ruled several years ago that Xenon violated a partnership agreement by failing to share revenues from Novartis "sublicense" deal. And the appeals court went even further than the lower court.

He said that after learning the Novartis case of a press release, WARF has the right to terminate the contract itself and claim ownership of some discoveries that have come out of the project. Specifically, the decision states that Wisconsin has property rights in the compounds of potential drugs studied by a biochemist from the University, Mark Gray-Keller, who was hired by Xenon on a consultancy agreement to test the activity the company's materials he wanted to check.

Xenon declined to comment. Calling the decision a "sweep" last night, the Advocate General of WARF Michael Falk, issued a statement saying, "We are extremely pleased with this decision. WARF is now free and clear to move the technology forward commercially and intends to do so. "

"Mine, all mine!" This is what the vaccinia virus seems to say after it invades a cell and prevents his companions to follow suit. But the behavior is selfish sentence. The researchers found that the strategy actually helps spread the virus as it speeds up the targeting of uninfected cells. This previously unknown mechanism may lead to new ways to fight against viral infections.

vaccinia does not cause disease in humans, but it helped us to fight them. Thank you to its resemblance to the smallpox virus, the researchers were able to use the vaccine as a vaccine against the disease, eventually leading to its eradication in the late 1970. Since then, scientists have continued to study vaccinia as a platform to develop vaccines against other diseases.

Nevertheless this study, researchers have lacked a curious feature of the biology of the virus, said virologist Geoffrey Smith of Imperial College London. While carefully watching the fields of cell destruction caused by the virus - called plaques - he and his colleagues noticed that vaccinia spread four times faster than its replication cycle would. "Nobody seemed to have done the math," says Smith.

So, Smith and colleagues dug a little deeper. They found that the vaccine produces two proteins right after it infects a cell. proteins work together to form a complex on the cell surface which prevents other vaccinia virus particles from entering (a process called superinfection). When other vaccinia virus impinge, long projections of another protein, actin, grows from the cell membrane, causing the virus to bounce. "the novelty here, with vaccinia, is that it is not only prevent the superinfecting virus, but physically it is repelling the virus away, "said Smith, whose team reports its findings today in Science .

many other viruses, such as herpes simplex virus, seem use similar infection strategies, Mr. Smith. Assuming they use the same protein complex as vaccinia, he says, researchers might be able to fight these infections by blocking the interaction of the two proteins.

cell biologist Michael Way of the London Research Institute accepts that other viruses can also use the strategy of infection with vaccinia virus. "I think it may be more general than people realize."